PPM1D, protein phosphatase Mn2+/Mg2+-dependent 1D, is a DNA damage response regulator that is frequently mutated in clonal hematopoiesis and is present in about 20% of patients with therapy-related AML or MDS; PPM1D mutations confer a survival advantage onto hematopoietic clones by rendering them resistant to DNA-damaging agents, such as cisplatin [13]. This evidence concerns the gene PPM1D and myelodysplastic syndrome.